NASDAQ:FSTX - F-star Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.33
  • Forecasted Upside: 218.87 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$10.14
▲ +0.84 (9.03%)
1 month | 3 months | 12 months
Get New F-star Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.33
▲ +218.87% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for F-star Therapeutics in the last 3 months. The average price target is $32.33, with a high forecast of $35.00 and a low forecast of $30.00. The average price target represents a 218.87% upside from the last price of $10.14.
Buy
The current consensus among 5 investment analysts is to buy stock in F-star Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2021OppenheimerInitiated CoverageOutperform$30.00High
i
4/14/2021William BlairInitiated CoverageOutperformLow
i
Rating by M. Phipps at William Blair
4/8/2021William BlairInitiated CoverageOutperformHigh
i
Rating by M. Phipps at William Blair
3/30/2021LaidlawInitiated CoverageBuy$32.00Low
i
3/24/2021LaidlawInitiated CoverageBuy$32.00High
i
3/8/2021HC WainwrightInitiated CoverageBuy$35.00High
i
Rating by P. Trucchio at HC Wainwright
3/1/2021HC WainwrightInitiated CoverageBuy$35.00Low
i
Rating by P. Trucchio at HC Wainwright
12/2/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
i
(Data available from 4/18/2016 forward)
F-star Therapeutics logo
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $10.14
$9.85
$10.42

50 Day Range

MA: $9.97
$7.09
$13.84

52 Week Range

Now: $10.14
$3.88
$15.50

Volume

392,949 shs

Average Volume

86,074 shs

Market Capitalization

$92.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Frequently Asked Questions

What sell-side analysts currently cover shares of F-star Therapeutics?

The following Wall Street sell-side analysts have issued reports on F-star Therapeutics in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, Laidlaw, Oppenheimer Holdings Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for FSTX.

What is the current price target for F-star Therapeutics?

3 Wall Street analysts have set twelve-month price targets for F-star Therapeutics in the last year. Their average twelve-month price target is $32.33, suggesting a possible upside of 218.9%. HC Wainwright has the highest price target set, predicting FSTX will reach $35.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $30.00 for F-star Therapeutics in the next year.
View the latest price targets for FSTX.

What is the current consensus analyst rating for F-star Therapeutics?

F-star Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FSTX will outperform the market and that investors should add to their positions of F-star Therapeutics.
View the latest ratings for FSTX.

What other companies compete with F-star Therapeutics?

How do I contact F-star Therapeutics' investor relations team?

F-star Therapeutics' physical mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company's listed phone number is 44 1223 497 400 and its investor relations email address is [email protected] The official website for F-star Therapeutics is www.f-star.com.